Drug Profile
Research programme: nicotinamide phosphoribosyltransferase inhibitors - Myrexis
Alternative Names: Cancer metabolism inhibitor programme; CMI programme; MPC-8640; MPC-9528; MPI-0486348; MPI-486348Latest Information Update: 26 Nov 2012
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer